Roche has secured the US Food and Drug Administration (FDA) approval for its cobas MPX test to be used on the cobas 6800 and 8800 Systems.

The cobas MPX test allows donor screening laboratories to apply PCR-based diagnostic technology to the surveillance of donated blood and plasma in the US, preventing the spread of Human Immunodeficiency Virus Groups 1 and 2 (HIV-1 and HIV-2), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) through transfused blood products.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Roche molecular diagnostics head Uwe Oberlaender said: "This approval reinforces our strong presence in donor screening, and underscores our ability to provide proven, robust technology for the testing of donated blood and blood products.

"The cobas MPX is a nucleic acid test developed to detect HIV, HBV and HCV in human blood plasma and serum."

 "We will continue to partner with donor screening laboratories worldwide demonstrating our joint commitment to patient safety."

The cobas MPX is a nucleic acid test developed to detect HIV, HBV and HCV in human blood plasma and serum.

See Also:

The real-time time PCR multiplex test can detect five critical viral targets which are HIV-1 Group M, HIV-1 Group O, HIV-2, HBV and HCV from a single sample.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

cobas MPX assay works with a dual-target approach with amplification of separate regions of HIV-1, and dual probes for HCV by eliminating the requirement for discriminatory testing between HIV, HBV, and HCV and the potential for discrepant results.

The cobas 6800 and cobas 8800 Systems are fully integrated, automated solutions facilitating molecular testing for donor screening, viral load monitoring, women's health and microbiology.

The systems are based on PCR technology, and are designed to deliver fully automated solutions with increased throughput and faster turnaround time, thereby boosting workflow efficiencies.